Treating acute myocardial infarction: something in the wind?

Lancet

Volumn 370, Issue 9597, 2007, Pages 1461-1462

  Bogle, Richard ^a   Wilkins, Martin ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYDECANOIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL BLOCKING AGENT; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP DEPENDENT PROTEIN KINASE; GLIBENCLAMIDE; GUANYLATE CYCLASE; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; NICORANDIL; NITRIC OXIDE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANGIOPLASTY; APOPTOSIS; ARTICLE; CELL DEATH; DRUG MECHANISM; EX VIVO STUDY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; IN VIVO STUDY; JAPAN; LONG TERM CARE; MITOCHONDRIAL PERMEABILITY; NATRIURESIS; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASODILATATION; WORKLOAD;

EID: 35448969684     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61612-2     Document Type: Note

References (12)

1. Bolli R., Becker L., Gross G., and for the NHLBI Working Group on the Translation of Therapies for Protecting the Heart from Ischemia. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 95 (2004) 125-134
2. Kitakaze M., Asakura M., Kim J., et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 370 (2007) 1483-1493
3. Richards A. Natriuretic peptides: update on peptide release, bioactivity and clinical use. Hypertension 50 (2007) 25-30
4. Burley D., Ferdinandy P., and Baxter G. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol (2007). DOI:10.1038/sj.bjp.0707409
5. Shanmuganathan S., Hausenloy D., Duchen M., and Yellon D. Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. Am J Physiol Heart Circ Physiol 289 (2005) H237-H242
6. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 33 (2001) 1897-1918
7. D'Souza S., Yellon D., Martin C., et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 284 (2003) 1592-1600
8. Okawa H., Horimoto H., Mieno S., Nomura Y., Yoshida M., and Shinjiro S. Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotective effects against ischemia reperfusion in isolated rat hearts. Mol Cell Biochem 248 (2003) 171-177
9. Ren B., Shen Y., Shao H., Qian J., Wu H., and Jing H. Brain natriuretic peptide limits myocardial infarct size dependent of nitric oxide synthase in rats. Clin Chim Acta 377 (2007) 83-87
10. Ishii H., Ichimiya S., Kanashiro M., et al. Effect of intravenous nicorandil and preexisting angina pectoris on short- and long-term outcomes in patients with a first ST-segment elevation acute myocardial infarction. Am J Cardiol 99 (2007) 1203-1207
11. Hayashi M., Tsutamoto T., Wada A., et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 37 (2001) 1820-1826
12. Topol E. Nesiritide-not verified. N Engl J Med 353 (2007) 113-116